ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: TH-PO024

Urinary DcR2/Cr Is Associated With Adverse Outcomes in Patients With AKI

Session Information

Category: Acute Kidney Injury

  • 102 AKI: Clinical‚ Outcomes‚ and Trials


  • Yi, Xiangling, Army Medical University, Chongqing, Chongqing, China
  • Chen, Jia, Army Medical University, Chongqing, Chongqing, China
  • He, Yani, Army Medical University, Chongqing, Chongqing, China

Acute kidney injury (AKI) is now considered a major public health problem affecting millions of people worldwide, and AKI is a significant risk of chronic kidney disease and end-stage renal disease. However, there is currently a lack of biomarkers for the prognosis of AKI. Decoy receptor 2 (DcR2), a senescent marker, is expressed exclusively in senescent tubular epithelia and urinary DcR2 (uDcR2) is associated with renal fibrosis in CKD. The aim of study is to investigate the relationship of uDcR2 with kidney injury and renal prognosis in patients with AKI.


130 biopsy-proven AKI patients were included from our hospital from January 2018 to February 2022. A composite renal endpoint included creatinine more than 50% higher than the baseline or ESRD after 90 days. All patients were divided into positive endpoints (n=63) and negative endpoints (n=64). The clinical characteristics were collected, and the pathological injury was scored. uDcR2 levels were measured using enzyme-linked immunosorbent assay and normalized to urinary cre (uDcR2/Cr). The correlation of uDcR2/Cr levels with renal function and renal pathological scores were analyzed. The logistic regression analysis was ued to investigate the assiociation of uDcR2/Cr with endpoints. The association of uDcR2/Cr with the composite renal endpoint using Kaplan-Meier curves were calculated.


The level of uDcR2/Cr was positively correlated with cystatin C, and negatively correlated with estimated glomerular filtration rate (eGFR). And uDcR2/Cr was positively associated with renal pathological scores, in including acute and chronic kidney injury. The risk factors for endpoint positive were uDcR2/Cr, pathological scores, male, and CKD history. Compared with endpoint-negative group, the uDcR2/Cr level of endpoint-positive patients was significantly higher. Among the patients with uDcR2/Cr < 433ng/g, the percentage of endpoint-negative AKI patients was the higher. And patients with uDcR2/Cr > 433ng/g are more likely to reach the renal end point.


Urinary DcR2/Cr is closely associated to kidney injury and renal prognosis of AKI, suggesting that uDcR2/Cr could sever as a novel biomarker for predicting adverse outcomes in patients with AKI.


  • Other U.S. Government Support